Attendee search 

NLC European Healthcare Venture Builder 是一家总部位于荷兰的欧洲医疗科技企业创设公司,在法国、德国和奥地利设有分支机构。NLC 每年筛选超过 3,000 项欧洲最新的医疗专利技术和发明,从中挑选出最具潜力的创新技术并创建公司。NLC 旗下已拥有数十家医疗科技企业,横跨治疗设备、诊断、影像、细胞疗法、AI 人工智能、神经网络、智慧医疗等国内热门医疗领域和紧缺方向,且在技术成熟度、治疗领域和技术类型上拥有充分的多样性,进一步分散了投资风险。

China Meheco Group Co., Ltd. (China Meheco), established in 1984, head office in Beijing. State-owned company listed at Shanghai Stock Exchange (No 600056).
The whole industry chain includes R&D, cultivation & processing, manufacturing, distribution, logistics, international trading, academic promotion, technical service etc.
The company has established a comprehensive business framework supported by pharmaceutical manufacture. The 12 drug plants of the Group system China Meheco are located in different regions in China. All production lines are proved by GMP, Good Manufacturing Practice, etc.

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Leading healthcare company in china

Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.

Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.

Distributer for pharmaceutical products

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.

Global leading Medtech company

生物科技公司